Guggenheim raised the firm’s price target on GoodRx to $10 from $8 and keeps a Buy rating on the shares after the company reported “strong results” in the quarter. While GoodRx lowered the high end of their 2023 revenue guidance range by about 2%, the firm believes that the company is going through a strategic shift through PBM partnerships and other initiatives that will fuel long-term growth, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GDRX: